RecruitingRecruiting
A Study of Azenosertib (ZN-c3) Versus Investigator's Choice Chemotherapy in Subjects With Platinum-Resistant High-Grade Serous Ovarian, Primary Peritoneal, or Fallopian Tube Cancers Positive for Cyclin E1 Protein Expression
NCT07546500 · K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc
In plain English
Click the button to translate this study into plain language — what it is, who qualifies, and what participation looks like.
Official title
A Randomized, Open-Label Phase 3 Study of Azenosertib Versus Investigator's Choice of Chemotherapy in Platinum-Resistant High-Grade Serous Ovarian, Primary Peritoneal, or Fallopian Tube Cancers Positive for Cyclin E1 Protein Expression
About this study
A Phase 3 study to evaluate the efficacy, safety, and overall clinical benefit of azenosertib (ZN-c3) compared with Investigator's choice of chemotherapy in subjects with Platinum-Resistant, High-Grade Serous Ovarian, Fallopian Tube, or Primary Peritoneal Cancer. Azenosertib is a selective and orally bioavailable inhibitor of WEE1. In HGSOC, high Cyclin E1 protein drives replication stress and increases tumor reliance on WEE1-mediated G2/M checkpoint control. Treating tumor cells with azenosertib promotes premature cell cycle progression leading to increased replication stress and accumulation of DNA damage pushing cells to mitotic catastrophe resulting in tumor cell death.
Eligibility criteria
Inclusion Criteria:
1. Female age ≥ 18 years
2. High-grade serous epithelial ovarian, primary peritoneal, or fallopian tube cancer
3. Measurable disease per RECIST Version 1.1
4. Eastern Cooperative Oncology Group (ECOG) performance status score 0-1
5. The subject's tumor tissue must be positive for cyclin E1 protein expression per the Sponsor's clinically validated cyclin E1 IHC investigational, in vitro diagnostic assay
6. Prior Therapy:
1. Subject must have platinum-resistant disease
2. One to 3 prior lines or regimens are allowed (1 to 4 prior lines are permitted, if prior mirvetuximab)
3. Prior bevacizumab treatment is required, if eligible per standard of care
4. Prior PARP inhibitor treatment is required if BRCA 1/2 mutation or HRD, if eligible per standard of care
5. Prior mirvetuximab treatment is required, if eligible per standard of care
7. Adequate hematologic and organ function during the screening period
Exclusion Criteria:
1. History of another malignancy in the previous 2 years, unless cured by surgery alone and continuously disease-free. Exceptions include appropriately treated carcinoma in situ of the cervix, nonmelanoma skin carcinoma, Stage 1 uterine cancer, or other malignancies with an expected curative outcome.
2. Subjects with primary platinum-refractory disease.
3. Prior therapy with azenosertib or any other WEE1 inhibitor, ATR inhibitor, CHK1/2 inhibitor, or (PKMYT1) inhibitor for PROC.
4. A serious illness or medical condition(s) including, but not limited to, the following:
1. Clinically or radiographically unstable brain metastases or leptomeningeal disease that requires immediate treatment. Subjects with asymptomatic brain metastases are eligible.
2. Acute kidney injury requiring intervention, or presence of indwelling urinary catheter or percutaneous nephrostomy.
3. Significant gastrointestinal abnormalities, including an inability to take oral medication, requirement for IV alimentation, active peptic ulcer, chronic diarrhea or vomiting considered to be clinically significant in the judgment of the Investigator, or prior surgical procedures affecting absorption.
4. Any evidence of small bowel obstruction as determined by air/fluid levels on computed tomography (CT) scan, recent hospitalization for small bowel obstruction within 3 months before randomization, or recurrent paracentesis or thoracentesis within 6 weeks before randomization.
5. Active, uncontrolled infection. Subjects with an infection receiving treatment (antibiotic, antifungal, or antiviral) must have completed such treatment and the infection must be considered controlled/resolved (and afebrile) by the Investigator for at least 7 days before randomization
6. Myocardial impairment of any cause resulting in heart failure by New York Heart Association criteria (Class II, III or IV).
7. Medical or psychiatric condition or laboratory abnormality that may increase the risk associated with study participation or may interfere with the interpretation of study results
5. Any of the following treatment interventions within the specified time frame before randomization:
1. Hospitalization within 14 days
2. Major surgery within 28 days
3. Any chemotherapy or targeted tumor therapy within 21 days or 5 half-lives (whichever is shorter)
4. Radiation therapy within 21 days
5. Autologous or allogeneic stem cell transplant within 3 months
6. Current use of any other investigational drug therapy \< 28 days or 5 half-lives (whichever is shorter)
6. Inability to discontinue treatment with prescription or nonprescription drugs that are prohibited per protocol.
7. Inability to discontinue consumption of food and herbal supplements that are prohibited per protocol
8. Prior wide-field radiotherapy affecting ≥ 20% of the bone marrow.
9. Unresolved toxicity of Grade \> 1 attributed to any prior therapies (excluding Grade ≤ 2 neuropathy, alopecia, or skin pigmentation).
10. Subjects who are immunocompromised or HIV-positive on highly active anti-retroviral therapy
11. Subjects with known active hepatitis B or hepatitis C infection
12. Individuals who are judged by the Investigator to be unsuitable as study subjects
Study design
Enrollment target: 420 participants
Allocation: randomized
Masking: none
Age groups: adult, older_adult
Timeline
Starts: 2026-04-17
Estimated completion: 2030-04-30
Last updated: 2026-11-09
Interventions
Drug: Investigator's choice of ChemotherapyDrug: Azenosertib
Primary outcomes
- • Progression free survival (PFS) per RECIST v1.1 as assessed by Investigator (Up to approximately 24 months from the enrollment of the last subject)
Sponsor
K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc · industry
With: European Network of Gynaecological Oncological Trial Groups (ENGOT), GOG Foundation
Contacts & investigators
ContactProject Director · contact · medicalaffairs@zentalis.com · 858.263.4333
All locations (129)
Site 0107Not Yet Recruiting
Phoenix, Arizona, United States
Site 0110Not Yet Recruiting
Antioch, California, United States
Site 0104Recruiting
Beverly Hills, California, United States
Site 0122Recruiting
Fountain Valley, California, United States
Site 0115Not Yet Recruiting
San Francisco, California, United States
Site 0101Recruiting
Torrance, California, United States
Site 0116Recruiting
Orlando, Florida, United States
Site 0123Recruiting
Baltimore, Maryland, United States
Site 0111Not Yet Recruiting
Camden, New Jersey, United States
Site 0108Not Yet Recruiting
Columbus, Ohio, United States
Site 0105Not Yet Recruiting
Portland, Oregon, United States
Site 0109Recruiting
Philadelphia, Pennsylvania, United States
Site 0113Not Yet Recruiting
Philadelphia, Pennsylvania, United States
Site 0114Not Yet Recruiting
Willow Grove, Pennsylvania, United States
Site 0112Not Yet Recruiting
Sioux Falls, South Dakota, United States
Site 0117Recruiting
Fort Worth, Texas, United States
Site 2105Not Yet Recruiting
Buenos Aires, Argentina
Site 2101Not Yet Recruiting
Córdoba, Argentina
Site 2102Not Yet Recruiting
Córdoba, Argentina
Site 2104Not Yet Recruiting
Rosario, Argentina
Site 2103Not Yet Recruiting
San Miguel de Tucumán, Argentina
Site 1101Recruiting
Randwick, New South Wales, Australia
Site 1105Not Yet Recruiting
Westmead, New South Wales, Australia
Site 1108Not Yet Recruiting
Wollongong, New South Wales, Australia
Site 1107Not Yet Recruiting
South Brisbane, Queensland, Australia
Site 1102Recruiting
Adelaide, South Australia, Australia
Site 1103Not Yet Recruiting
Nedlands, Western Australia, Australia
Site 1104Not Yet Recruiting
Subiaco, Western Australia, Australia
Site 3002Recruiting
Brussels, Belgium
Site 3003Not Yet Recruiting
Edegem, Belgium
Site 3001Not Yet Recruiting
Leuven, Belgium
Site 2209Not Yet Recruiting
Belo Horizonte, Brazil
Site 2208Not Yet Recruiting
Curitiba, Brazil
Site 2207Not Yet Recruiting
Goiânia, Brazil
Site 2201Not Yet Recruiting
Porto Alegre, Brazil
Site 2203Not Yet Recruiting
Porto Alegre, Brazil
Site 2205Not Yet Recruiting
Rio de Janeiro, Brazil
Site 2206Not Yet Recruiting
Rio de Janeiro, Brazil
Site 2202Not Yet Recruiting
São José do Rio Preto, Brazil
Site 2204Not Yet Recruiting
São Paulo, Brazil
Site 0207Not Yet Recruiting
Vancouver, British Columbia, Canada
Site 0205Not Yet Recruiting
Toronto, Ontario, Canada
Site 0201Not Yet Recruiting
Toronto, Ontario, Canada
Site 0203Not Yet Recruiting
Montreal, Quebec, Canada
Site 0206Not Yet Recruiting
Montreal, Quebec, Canada
Site 0202Not Yet Recruiting
Sherbrooke, Quebec, Canada
Site 3103Not Yet Recruiting
Rijeka, Croatia
Site 3101Not Yet Recruiting
Zagreb, Croatia
Site 3102Not Yet Recruiting
Zagreb, Croatia
Site 3203Not Yet Recruiting
Aalborg, Denmark
Site 3201Not Yet Recruiting
Copenhagen, Denmark
Site 3202Not Yet Recruiting
Roskilde, Denmark
Site 3302Not Yet Recruiting
Tallinn, Estonia
Site 3301Not Yet Recruiting
Tartu, Estonia
Site 3403Not Yet Recruiting
Kuopio, Finland
Site 3401Not Yet Recruiting
Oulu, Finland
Site 3402Not Yet Recruiting
Tampere, Finland
Site 3508Not Yet Recruiting
Besançon, France
Site 3502Not Yet Recruiting
Brest, France
Site 3507Not Yet Recruiting
Dijon, France
Site 3504Not Yet Recruiting
Lyon, France
Site 3510Not Yet Recruiting
Marseille, France
Site 3503Not Yet Recruiting
Paris, France
Site 3501Not Yet Recruiting
Pierre-Bénite, France
Site 3509Not Yet Recruiting
Saint-Herblain, France
Site 3505Not Yet Recruiting
Strasbourg, France
Site 3506Recruiting
Villejuif, France
Site 3602Not Yet Recruiting
Berlin, Germany
Site 3603Not Yet Recruiting
Bonn, Germany
Site 3601Not Yet Recruiting
Dresden, Germany
Site 3605Not Yet Recruiting
Düsseldorf, Germany
Site 3604Not Yet Recruiting
Tübingen, Germany
Site 3703Not Yet Recruiting
Cork, Ireland
Site 3704Not Yet Recruiting
Dublin, Ireland
Site 3702Not Yet Recruiting
Dublin, Ireland
Site 5009Not Yet Recruiting
Ashdod, Israel
Site 5002Not Yet Recruiting
Haifa, Israel
Site 5007Not Yet Recruiting
Holon, Israel
Site 5001Not Yet Recruiting
Jerusalem, Israel
Site 5006Not Yet Recruiting
Nahariya, Israel
Site 5003Not Yet Recruiting
Petah Tikva, Israel
Site 5008Not Yet Recruiting
Safed, Israel
Site 5004Not Yet Recruiting
Tel Aviv, Israel
Site 5005Not Yet Recruiting
Tel HaShomer, Israel
Site 3801Not Yet Recruiting
Bologna, Italy
Site 3814Not Yet Recruiting
Florence, Italy
Site 3805Not Yet Recruiting
Milan, Italy
Site 3804Not Yet Recruiting
Milan, Italy
Site 3803Not Yet Recruiting
Milan, Italy
Site 3812Not Yet Recruiting
Milan, Italy
Site 3813Not Yet Recruiting
Milan, Italy
Site 3802Not Yet Recruiting
Naples, Italy
Site 3808Not Yet Recruiting
Pisa, Italy
Site 3807Not Yet Recruiting
Prato, Italy
Site 3810Not Yet Recruiting
Roma, Italy
Site 3806Not Yet Recruiting
Rome, Italy
Site 3811Not Yet Recruiting
Torino, Italy
Site 3809Not Yet Recruiting
Vicenza, Italy
Site 3901Not Yet Recruiting
Amsterdam, Netherlands
Site 3902Not Yet Recruiting
Groningen, Netherlands
Site 3903Not Yet Recruiting
Nijmegen, Netherlands
Site 4005Not Yet Recruiting
Gdansk, Poland
Site 4006Not Yet Recruiting
Krakow, Poland
Site 4008Not Yet Recruiting
Krakow, Poland
Site 4004Not Yet Recruiting
Poznan, Poland
Site 4002Not Yet Recruiting
Poznan, Poland
Site 4007Not Yet Recruiting
Siedlce, Poland
Site 4003Not Yet Recruiting
Szczecin, Poland
Site 4106Not Yet Recruiting
Coimbrã, Portugal
Site 4104Not Yet Recruiting
Lisbon, Portugal
Site 4103Not Yet Recruiting
Lisbon, Portugal
Site 4102Not Yet Recruiting
Lisbon, Portugal
Site 4105Not Yet Recruiting
Lisbon, Portugal
Site 4101Not Yet Recruiting
Porto, Portugal
Site 0137Recruiting
San Juan, Puerto Rico
Site 1203Recruiting
Daegu, South Korea
Site 1206Recruiting
Goyang-si, South Korea
Site 1202Recruiting
Seoul, South Korea
Site 1205Recruiting
Seoul, South Korea
Site 1204Recruiting
Seoul, South Korea
Site 1201Recruiting
Seoul, South Korea
Site 4201Not Yet Recruiting
Barcelona, Spain
Site 4205Not Yet Recruiting
Barcelona, Spain
Site 4202Recruiting
Madrid, Spain
Site 4206Not Yet Recruiting
Madrid, Spain
Site 4203Not Yet Recruiting
Málaga, Spain
Site 4204Recruiting
Vigo, Spain
Site 1301Not Yet Recruiting
Taichung, Taiwan
Site 1302Not Yet Recruiting
Taipei, Taiwan